PubMed · 2015 · 47 citations · 24 references
MedicineOncologyMedical OncologySurvival AnalysisThoracic OncologyCancer Survival AnalysisLung CancerLung Cancer PharmacotherapyPrognostic AssessmentSurvival OutcomesCox RegressionDefinitive Concurrent ChemoradiationDistant Metastasis-free SurvivalNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPrimary Outcome AnalysisPrognostic Factors AnalysisRecurrence-free Survival
BACKGROUND: We investigated survival outcomes in diabetic patients with non-small cell lung cancer (NSCLC) treated with concurrent metformin and definitive chemoradiation. METHODS: This single-institution, retrospective cohort study included 166 patients with NSCLC who were treated definitively with chemoradiation between 1999 and 2013. Of 40 patients who had type II diabetes, 20 (50%) were on metformin, and 20 (50%) were not on metformin. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival (PFS), locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS). Kaplan Meier method and log-rank test were performed in survival analysis. Cox regression was utilized in univariate analysis of potential confounders. RESULTS: Median follow-up was 17.0 months. Compared with non-diabetic patients, diabetic patients on metformin demonstrated similar OS (16.3 vs. 14.3 mo, P=0.23), PFS (11.6 vs. 9.7 mo, P=0.26), LRRFS (14.1 vs. 11.9 mo, P=0.78), and DMFS (13.4 vs. 10.0 mo, P=0.69). Compared with diabetic patients not on metformin, diabetic patients on metformin also exhibited similar OS (14.3 vs. 19.2 mo, P=0.18), PFS (19.7 vs. 10.1 mo, P=0.38), LRRFS (11.9 vs. 15.5 mo, P=0.69), and DMFS (10.0 vs. 17.4 mo, P=0.12). Identified negative prognostic factors on included squamous cell histology, lower performance status, higher T stage, and non-caucasian ethnicity. CONCLUSIONS: No statistically significant differences in survival or patterns of failure were found among the three cohorts in this small set of patients. No statistically significant differences in survival or patterns of failure were found between the three cohorts in this small set of patients. Though it is possible that metformin use may in fact have no effect on survival in NSCLC patients treated with definitive RT, larger-scale retrospective and prospective studies are implicated for clarification.
24
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2013 · 11.9K citations · Full text
The Medical Journal of Australia · 1976 · 5.3K citations
Brenda K. Edwards, Elizabeth Ward, Betsy Kohler et al. · Cancer · 2009 · 2K citations · Full text
Medicine, Biostatistics, Oncology +17
Principles and Practice of Radiation Oncology
Carlos Pérez, Luther W. Brady · Journal of Pediatric Hematology/Oncology · 1999 · 1.9K citations